BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22035568)

  • 1. Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model.
    Hobbs M; Parker C; Birch H; Kenworthy K
    Xenobiotica; 2012 Apr; 42(4):327-38. PubMed ID: 22035568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.
    Pfeifer ND; Bridges AS; Ferslew BC; Hardwick RN; Brouwer KL
    J Pharmacol Exp Ther; 2013 Dec; 347(3):737-45. PubMed ID: 24080682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition I: characterization of basolateral versus biliary clearance using a novel protocol in sandwich-cultured hepatocytes.
    Pfeifer ND; Yang K; Brouwer KL
    J Pharmacol Exp Ther; 2013 Dec; 347(3):727-36. PubMed ID: 24023367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
    Kitamura S; Maeda K; Wang Y; Sugiyama Y
    Drug Metab Dispos; 2008 Oct; 36(10):2014-23. PubMed ID: 18617601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
    Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
    Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
    Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
    Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier.
    Ose A; Kusuhara H; Endo C; Tohyama K; Miyajima M; Kitamura S; Sugiyama Y
    Drug Metab Dispos; 2010 Jan; 38(1):168-76. PubMed ID: 19833843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
    Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
    J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure.
    Iusuf D; van Esch A; Hobbs M; Taylor M; Kenworthy KE; van de Steeg E; Wagenaar E; Schinkel AH
    Mol Pharmacol; 2013 May; 83(5):919-29. PubMed ID: 23429889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An experimental approach to evaluate the impact of impaired transport function on hepatobiliary drug disposition using Mrp2-deficient TR- rat sandwich-cultured hepatocytes in combination with Bcrp knockdown.
    Yang K; Pfeifer ND; Hardwick RN; Yue W; Stewart PW; Brouwer KL
    Mol Pharm; 2014 Mar; 11(3):766-75. PubMed ID: 24410402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin.
    Deng JW; Shon JH; Shin HJ; Park SJ; Yeo CW; Zhou HH; Song IS; Shin JG
    Pharm Res; 2008 Aug; 25(8):1807-14. PubMed ID: 18236139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The hepatobiliary disposition of timosaponin b2 is highly dependent on influx/efflux transporters but not metabolism.
    Sheng J; Tian X; Xu G; Wu Z; Chen C; Wang L; Pan L; Huang C; Pan G
    Drug Metab Dispos; 2015 Jan; 43(1):63-72. PubMed ID: 25336752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
    Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
    Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of a basolateral transporter in rosuvastatin transport and its interplay with apical breast cancer resistance protein in polarized cell monolayer systems.
    Li J; Wang Y; Zhang W; Huang Y; Hein K; Hidalgo IJ
    Drug Metab Dispos; 2012 Nov; 40(11):2102-8. PubMed ID: 22855735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
    Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
    Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling.
    Bosgra S; van de Steeg E; Vlaming ML; Verhoeckx KC; Huisman MT; Verwei M; Wortelboer HM
    Eur J Pharm Sci; 2014 Dec; 65():156-66. PubMed ID: 25261337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin.
    Windass AS; Lowes S; Wang Y; Brown CD
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1221-7. PubMed ID: 17585018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ethnic differences in statin disposition.
    Tirona RG
    Clin Pharmacol Ther; 2005 Oct; 78(4):311-6. PubMed ID: 16198649
    [No Abstract]   [Full Text] [Related]  

  • 19. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.
    Tomita Y; Maeda K; Sugiyama Y
    Clin Pharmacol Ther; 2013 Jul; 94(1):37-51. PubMed ID: 23443754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.